Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Total Current Liabilities (2016 - 2025)

UroGen Pharma's Total Current Liabilities history spans 10 years, with the latest figure at $46.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 1.02% year-over-year to $46.4 million; the TTM value through Dec 2025 reached $46.4 million, up 1.02%, while the annual FY2025 figure was $46.4 million, 1.02% up from the prior year.
  • Total Current Liabilities reached $46.4 million in Q4 2025 per URGN's latest filing, up from $42.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $47.5 million in Q2 2025 to a low of $17.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $29.2 million, with a median of $26.1 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: dropped 5.33% in 2022, then surged 59.45% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $22.4 million in 2021, then increased by 6.86% to $23.9 million in 2022, then soared by 30.51% to $31.2 million in 2023, then skyrocketed by 47.22% to $45.9 million in 2024, then grew by 1.02% to $46.4 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Total Current Liabilities are $46.4 million (Q4 2025), $42.2 million (Q3 2025), and $47.5 million (Q2 2025).